Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc Ultragenyx DTX401 Phase 1/2 Cohort 2 Data Conference Call Transcript

Sep 04, 2019 / 12:30PM GMT
Release Date Price: MXN1069.95
Operator

Good day, ladies and gentlemen.

Welcome to the Ultragenyx DTX401 Data Conference Call.

(Operator Instructions)

I would now like to turn the call over to Ms. Danielle Keatley, Senior Director of Investor Relations. Ma'am, you may begin.

Danielle Keatley
Ultragenyx Pharmaceutical Inc. - Senior Director of IR & Corporate Communications

Thank you.

Good morning and welcome to the Ultragenyx Conference Call to discuss the interim results of the Phase I/II study of DTX401, our gene therapy for the treatment of GSDIa. These results were presented at the SSIEM Annual Symposium earlier today, and we issued a press release detailing the data results. Both the press release and the SSIEM presentation can be found on our website at ultragenyx.com.

With me today are Emil Kakkis, Chief Executive Officer and President of Ultragenyx; and Dr. David Weinstein, Professor and Director, Glycogen Storage Disease Program at Connecticut Children's Medical Center and UConn Health.

I would like to remind investors that this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot